Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBet v 1 SLIT in Birch Pollen Rhinoconjunctivitis
NCT00901914Phase 2Completed
- Sponsor
- Stallergenes Greer
- Start
- Oct 2008
- Primary completion
- Jun 2009
- Modality
- Peptides, Peptide-based Cancer Vaccines, Allergy Immunotherapy
- Countries
- 8
01
Overview
A Phase 2 trial of recombinant Bet v 1 in birch pollen allergy, sponsored by Stallergenes Greer. Started Oct 2008; status: completed.
02
Drugs
recombinant Bet v 1
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT00901914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901914.